|
July 09
SemBioSys awarded
key U.S. patent for the production of insulin in plants
SemBioSys announces
non-binding letter of intent with Avrio Ventures Limited
Partnership and Botaneco
May 09
SemBioSys appoints
new board member
March 09
SemBioSys
announces 2008 financial and operational results
January 09
SemBioSys
receives US$2.5 million from option agreement with MannKind for
plant-produced insulin
December 08
SemBioSys
receives US$2.5 million in option agreement with MannKind for
plant-produced insulin
SemBioSys
begins phase I/II trial of insulin produced in plant seeds
September 08
SemBioSys
eligible to proceed with Phase I/II plant-produced insulin trial
after submission of IND
August 08
SemBioSys
announces second quarter 2008 financial and operational results
July 08
SemBioSys submits
Investigational New Drug for safflower-produced insulin to U.S.
Food and Drug Administration
March 08
SemBioSys
announces 2007 financial and operational results
SemBioSys' GLA
partner enters strategic alliance for the sale and marketing of
GLA-rich safflower oil
February 08
U.S.
Federal Register:
Availability of
an environmental assessment and finding of no significant impact
for a proposed field release of genetically engineered safflower
January 08
SemBioSys signs
option agreement for safflower-produced food ingredient
October 07
SemBioSys
confirms commercially viable levels of native APO AI in
safflower seed lines
August 07
Sembiosys
announces 2007 second quarter results - Canadian biotechnology
company achieves commercially viable levels of second
recombinant protein in plants
June 07
U.S.
Federal Register:
SemBioSys Genetics, Inc.: Availability of an environmental
assessment for a field release of safflower genetically
engineered to produce human proinsulin
May 07
SemBioSys CEO named
as an officer of the BIO Board of Directors
SemBioSys announces
first quarter results
March 07
SemBioSys
announces 2006 results
January 07
Sembiosys'
plant-produced insulin is chemically and physiologically
equivalent to commercial insulin in animal studies - Canadian
biotechnology company takes next significant step towards
advancing its product to the clinic
SemBioSys to proceed
with abbreviated regulatory path for plant-produced insulin after
meeting with the FDA
November 06
SemBioSys signs
contract manufacturing agreement for plant-produced insulin with Cangene
SemBioSys announces
third quarter results
SemBioSys announces
successful outcome of personal care product appeal proceedings at the
European Patent Office - Canadian biotechnology company's intellectual
property position strengthened by decision
August 06
SemBioSys Genetics
announces second quarter operational and financial results
July 06
SemBioSys Genetics achieves
commercially viable level of insulin in safflower
June 06
SemBioSys obtains rights to
platform-enhancing technologies from Syngenta
May 06
SemBioSys announces first
quarter operational and financial results
April 06
SemBioSys
completes gamma linolenic
acid rich safflower oil project, exceeds milestone targets for GLA
accumulation
March 06
SemBioSys announces 2005
year-end operational and financial results
November 05
SemBioSys reports
positive preclinical results of plant produced insulin in the Plant
Biotechnology Journal
SemBioSys announces
third quarter results
June 05
SemBioSys announces second
quarter results
May 05
SemBioSys Genetics announces
first quarter operational and financial results
March 05
SemBioSys announces
management’s nominations for election to its Board of Directors
SemBioSys announces 2004
year-end operational and financial results
November 04
SemBioSys receives U.S.
patent for plant seed based vaccine production
June 04
Arcadia Biosciences enters
into funded agreement with Sembiosys to support its program for GLA
safflower
May 04
SemBioSys executes
development agreement with Arcadia Biosciences
SemBioSys signs feasibility
agreement with Dow AgroSciences
February 04
SemBioSys Genetics and
Syngenta enter into agreement on protein and antibody purification
technology
December 03
SemBioSys executes
development agreement with Martek Biosciences
April 03
SemBioSys Genetics Inc.
to receive up to C$2.5
million from AVAC Ltd.
May 02
SemBioSys Genetics receives
ninth U.S. patent for oil body-based technology
February 02
SemBioSys Genetics
appoints Jeff Craig Vice President of Business Development -- Former
Monsanto executive to lead commercialization effort for Stratosome™
Production System
January 02
SemBioSys Genetics Inc.
to receive $CAN2.4 million from AVAC Limited
December 01
SemBioSys Genetics
Inc. formally opens new corporate headquarters
November 01
SemBioSys Genetics Inc.
to receive $5.5 million from Industry Canada
October
01
SemBioSys
Genetics receives US patent for its plant-based somatotropin production
technology
January
00
SemBioSys
Genetics announces product development agreement with Novartis
Agricultural Discovery Institute
December 98
SemBioSys
plans to scale up production facility
SemBioSys
Genetics Inc. - The Story of Molecular Farming
September 98
Dow announces biotechnology
strategy
August 98
Canadian biotechnology
company attracts industry leader
December 97
DowElanco invests $17 million to
bring new technology to world market
|
